JAK 1/2 Blockade in MDA5 Gain-of-Function

被引：26

作者：

McLellan, Kirsty E. ^{[1
]}

Martin, Neil ^{[1
]}

Davidson, Joyce E. ^{[1
]}

Cordeiro, Nuno ^{[2
]}

Oates, Bridget D. ^{[3
]}

Neven, Benedicte ^{[4
,5
,6
]}

Rice, Gillian I. ^{[7
]}

Crow, Yanick J. ^{[8
,9
]}

机构：

[1] Royal Hosp Children, Paediat Rheumatol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland

[2] Ayrshire Gen Hosp, Rainbow House Child Dev Ctr, Kilwinning Rd, Irvine KA128SS, England

[3] Univ Hosp Crosshouse, Paediat, Kilmarnock, East Ayrshire, Scotland

[4] Hop Necker Enfants Malad, AP HP, Pediat Hematol Immunol & Rheumatol Dept, Paris, France

[5] Paris Descartes Univ, Sorbonne Paris Cite, Inst Imagine, Paris, France

[6] INSERM, Lab Immunogenet Pediat Autoimmun, UMR 1163, Paris, France

[7] Univ Manchester, Sch Biol Sci, Div Evolut & Genom Sci, Manchester, Lancs, England

[8] Univ Edinburgh, MRC Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland

[9] Paris Descartes Univ, Sorbonne Paris Cite, Lab Neurogenet & Neuroinflammat, Inst Imagine, Paris, France

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2018年 / 38卷 / 08期

基金：

欧洲研究理事会;

关键词：

RUXOLITINIB;

D O I：

10.1007/s10875-018-0563-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：844 / 846

页数：3

共 7 条

[1] Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children [J].

Fremond, Marie-Louise ;

Rodero, Mathieu Paul ;

Jeremiah, Nadia ;

Belot, Alexandre ;

Jeziorski, Eric ;

Duffy, Darragh ;

Bessis, Didier ;

Cros, Guilhem ;

Rice, Gillian I. ;

Charbit, Bruno ;

Hulin, Anne ;

Khoudour, Nihel ;

Caballero, Consuelo Modesto ;

Bodemer, Christine ;

Fabre, Monique ;

Berteloot, Laureline ;

Le Bourgeois, Muriel ;

Reix, Philippe ;

Walzer, Thierry ;

Moshous, Despina ;

Blanche, St Ephane ;

Fischer, Alain ;

Bader-Meunier, Brigitte ;

Rieux-Laucat, Frederic ;

Crow, Yanick Joseph ;

Neven, Benedicte .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (06) :1752-1755

[2] NEUROMYELITIS OPTICA IN A CHILD WITH AICARDI-GOUTIERES SYNDROME [J].

Hacohen, Yael ;

Zuberi, Sameer ;

Vincent, Angela ;

Crow, Yanick J. ;

Cordeiro, Nuno .

NEUROLOGY, 2015, 85 (04) :381-383

[3] An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation [J].

Kothur, Kavitha ;

Bandodkar, Sushil ;

Chu, Stephanie ;

Wienholt, Louise ;

Johnson, Alexandra ;

Barclay, Peter ;

Brogan, Paul A. ;

Rice, Gillian I. ;

Crow, Yanick J. ;

Dale, Russell C. .

NEUROLOGY, 2018, 90 (06) :289-291

[4] Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study [J].

Rice, Gillian I. ;

Forte, Gabriella M. A. ;

Szynkiewicz, Marcin ;

Chase, Diana S. ;

Aeby, Alec ;

Abdel-Hamid, Mohamed S. ;

Ackroyd, Sam ;

Allcock, Rebecca ;

Bailey, Kathryn M. ;

Balottin, Umberto ;

Barnerias, Christine ;

Bernard, Genevieve ;

Bodemer, Christine ;

Botella, Maria P. ;

Cereda, Cristina ;

Chandler, Kate E. ;

Dabydeen, Lyvia ;

Dale, Russell C. ;

De Laet, Corinne ;

De Goede, Christian G. E. L. ;

del Toro, Mireia ;

Effat, Laila ;

Nunez Enamorado, Noemi ;

Fazzi, Elisa ;

Gener, Blanca ;

Haldre, Madli ;

Lin, Jean-Pierre S-M ;

Livingston, John H. ;

Lourenco, Charles Marques ;

Marques, Wilson, Jr. ;

Oades, Patrick ;

Peterson, Paert ;

Rasmussen, Magnhild ;

Roubertie, Agathe ;

Schmidt, Johanna Loewenstein ;

Shalev, Stavit A. ;

Simon, Rogelio ;

Spiegel, Ronen ;

Swoboda, Kathryn J. ;

Temtamy, Samia A. ;

Vassallo, Grace ;

Vilain, Catheline N. ;

Vogt, Julie ;

Wermenbol, Vanessa ;

Whitehouse, William P. ;

Soler, Doriette ;

Olivieri, Ivana ;

Orcesi, Simona ;

Aglan, Mona S. ;

Zaki, Maha S. .

LANCET NEUROLOGY, 2013, 12 (12) :1159-1169

[5] Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview [J].

Rodero, Mathieu P. ;

Crow, Yanick J. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 213 (12) :2527-2538

[6] JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies [J].

Sanchez, Gina A. Montealegre ;

Reinhardt, Adam ;

Ramsey, Suzanne ;

Wittkowski, Helmut ;

Hashkes, Philip J. ;

Berkun, Yackov ;

Schalm, Susanne ;

Murias, Sara ;

Dare, Jason A. ;

Brown, Diane ;

Stone, Deborah L. ;

Gao, Ling ;

Klausmeier, Thomas ;

Foell, Dirk ;

De Jesus, Adriana A. ;

Chapelle, Dawn C. ;

Kim, Hanna ;

Dill, Samantha ;

Colbert, Robert A. ;

Failla, Laura ;

Kost, Bahar ;

O'Brien, Michelle ;

Reynolds, James C. ;

Folio, Les R. ;

Calvo, Katherine R. ;

Paul, Scott M. ;

Weir, Nargues ;

Brofferio, Alessandra ;

Soldatos, Ariane ;

Biancotto, Angelique ;

Cowen, Edward W. ;

Digiovanna, John J. ;

Gadina, Massimo ;

Lipton, Andrew J. ;

Hadigan, Colleen ;

Holland, Steven M. ;

Fontana, Joseph ;

Alawad, Ahmad S. ;

Brown, Rebecca J. ;

Rother, Kristina I. ;

Heller, Theo ;

Brooks, Kristina M. ;

Kumar, Parag ;

Brooks, Stephen R. ;

Waldman, Meryl ;

Singh, Harsharan K. ;

Nickeleit, Volker ;

Silk, Maria ;

Prakash, Apurva ;

Janes, Jonathan M. .

JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (07) :3041-3052

[7] Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis [J].

Tefferi, Ayalew ;

Pardanani, Animesh .

MAYO CLINIC PROCEEDINGS, 2011, 86 (12) :1188-1191

← 1 →